Short-acting modified GHRH(1–29) analogue, commonly called Mod GRF 1–29
PRODUCT PROFILE
CJC-1295 No DAC
Price range: £25.99 through £32.99
CJC-1295 No DAC is short-acting modified ghrh(1–29) analogue, commonly called mod grf 1–29. Researchers examine it in relation to brief pituitary growth-hormone release through the ghrh receptor.
Why it is distinct
Short-duration GHRH signalling, in contrast with albumin-bound, long-acting CJC-1295 DAC.
- Evidence stageEarly human evidence
- AvailabilityUnavailable
- Batch recordPublished after verification
- DispatchConfirmed at checkout
PRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
CJC-1295 No DAC is short-acting modified ghrh(1–29) analogue, commonly called mod grf 1–29. Researchers examine it in relation to brief pituitary growth-hormone release through the ghrh receptor.
Research focus+
Researchers study its brief, pulse-like effect on growth-hormone signalling. It is not the same as long-acting CJC-1295 DAC and is not an authorised treatment.
How the mechanism differs+
Activates pituitary GHRH receptors but lacks the drug-affinity-complex group that gives CJC-1295 DAC albumin binding.
Evidence and limitations+
The no-DAC catalogue name is not standardised; direct human evidence is limited and identity should be confirmed by sequence.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers study its brief, pulse-like effect on growth-hormone signalling. It is not the same as long-acting CJC-1295 DAC and is not an authorised treatment.
Activates pituitary GHRH receptors but lacks the drug-affinity-complex group that gives CJC-1295 DAC albumin binding.
Short-duration GHRH signalling, in contrast with albumin-bound, long-acting CJC-1295 DAC.
The no-DAC catalogue name is not standardised; direct human evidence is limited and identity should be confirmed by sequence.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Experimental
Follistatin 344
£76.001 mgBatch file pendingA ligand-binding inhibitor of the activin/myostatin system, not a GH or IGF secretagogue.
UnavailableAsk about availability -
Established
Sermorelin
£49.005 mgBatch file pendingClosest to the natural active GHRH sequence and shorter acting than tesamorelin or CJC-1295 DAC.
UnavailableAsk about availability -
Early human evidence
Hexarelin
£51.005 mgBatch file pendingA potent older GHRP with less hormonal selectivity than ipamorelin.
UnavailableAsk about availability -
Early human evidence
GHRP-2
£44.005 mgBatch file pendingTypically characterised as a strong GH secretagogue with less appetite emphasis than GHRP-6.
UnavailableAsk about availability